Harpoon Therapeutics to Present Preclinical Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer
Abstract details:
Title: TriTAC-XR is an extended-release T cell engager platform designed to minimize cytokine release syndrome by reducing Cmax in systemic circulation
Abstract #: 867
Author:
Session Category: Novel Single-Agent Immunotherapies
Poster Presentation Date and Time:
The full abstract will be released on
For more details about the SITC Virtual Annual Meeting please visit: https://www.sitcancer.org/2021/home.
About
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. For additional information about
Contacts:
Chief Financial Officer
650-443-7400
media@harpoontx.com
Westwicke ICR
Managing Director
858-356-5932
robert.uhl@westwicke.com

Source: Harpoon Therapeutics